Gadkari, Abhijit
Regeneron (United States)
3 papers on CoChat
Most cited papers
- Verified
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine
Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis
Cited by 2,110
- Verified
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Deleuran, M., Thaçi, D., Beck, L. A., de Bruin-Weller, M., Blauvelt, A., Forman, S., Bissonnette, R., Reich, K., Soong, W., Hussain, I., et al. (2020) · Journal of the American Academy of Dermatology
Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis
Cited by 255
- Verified
Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom
Eckert, L., Gupta, S., Gadkari, A., Mahajan, P., & Gelfand, J. M. (2019) · Journal of the American Academy of Dermatology
Dermatology and Skin DiseasesContact Dermatitis and Allergies
Cited by 113
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free